Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Investor Presentation (March 2025)
26 slides from Viemed Healthcare's investor presentation, March 2025
Slide 1: Leading the Healthcare Industry in Home Respiratory Care
Investor Presentation: Leading the NASDAQ: VMD Healthcare Industry in Home Respiratory Care March 2025 VieMed Healthcare Inc. • Investor Presentation
Slide 2: Disclaimers and Other Important Information
Disclaimers Disclaimers and Other Important Information This presentation (the “Presentation”) about Viemed Healthcare, Inc. (“Viemed” or the “Company”) is dated as March 2025. It is information in a summary form and does not purport to be complete. The data contained herein is derived from various
Slide 3: A national, innovative in-home healthcare leader...
A national, innovative in-home healthcare leader... National Leader in Complex Innovative At-Home Robust Growth and Extensive Nationwide Respiratory Services Healthcare Financial Performance Reach VieMed is an in-home clinical care We focus on efficient and effective VieMed has achieved a remarkable
Slide 4: ...with multiple catalysts driving our growth
...with multiple catalysts driving our growth A vital link between patients, providers, and payors with an earned place in the home • High-touch, technology-enabled clinical approach to delivering complex respiratory services in the home provides significant competitive advantages • Proven partner f
Slide 5: Core business growth and attractive vent economics...
Core business growth and attractive vent economics... 1 VieMed Vent Rental Patients • $1,050 approximate monthly 12,500 reimbursement rate 11,500 • Covered by Medicare and most insurance plans 10,500 • Uncapped rental, ~17-month average 9,500 length of stay 8,500 • Bundled pricing includes equipment
Slide 6: ...Deployed across a massively underserved population...
...Deployed across a massively underserved population... 25 Million (estimated) people in the U.S. have COPD VIEMED IS THIRD 2,500,000 or 10% have stage 4 COPD 12% LARGEST PROVIDER* 1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy MA
Slide 7: ...Combined with a distinct competitive advantage...
...Combined with a distinct competitive advantage... Proprietary clinical Increase patient and platform, connecting best-in-class clinical 24/7 caregiver engagement service with Respiratory best-in-class devices Therapist included in service Increase efficiency Capture value-based data of clinicians
Slide 8: ...And backed by real-world results...
...And backed by real-world results... June 29, 2022 September 15, 2021 December 29, 2020 Early initiation of non-invasive ventilation at Non-invasive ventilation at home Non-invasive ventilation at home reduces Non-invasive ventilation at home improves home reduces mortality, hospitalizations, and
Slide 9: ...Drive our organic growth engine
...Drive our organic growth engine Location selection • Based on high COPD rates • Target hospitals and facilities struggling with length of stay management and near existing service area • Leverage existing relationships and operate heavily in rural markets Unique lean deployment model • No costly
Slide 10: We have transformed the business in the past five years...
We have transformed the business in the past five years... Diverse and Reliable Revenue Streams VieMed boasts a resilient and diversified payer base, benefiting from a favorable reimbursement environment that supports our sustained growth and operational excellence. SERVICE MIX PAYER MIX FY 2019 FY
Slide 11: ...With a growing sleep therapy and resupply business...
...With a growing sleep therapy and resupply business… 2 PAP Therapy Patients 1 Sleep Resupply Patients 30,000 • Acquisition of Home Medical Products Inc. (HMP) on June 1, 2023, accelerated 25,000 growth in the sleep market with a mature resupply program 20,000 • PAP therapy is a capped rental, whil
Slide 12: ...And added other services to expand our reach...
...And added other services to expand our reach… • Other major product synergies include oxygen and percussion vests • Device rentals generally subject to lifetime caps • Generally lower capital outlays, resulting in higher free cash flow • High-volume touchpoints build strong relationships with ref
Slide 13: ...While successfully executing on inorganic growth
...While successfully executing on inorganic growth • Robust M&A pipeline focuses on adding Strategic Acquisitions complementary services that can expand our • Acquired Home Medical Products, Inc. core businesses (HMP) in June 2023 • Immediately accretive to net income and EPS • New opportunities ar
Slide 14: Financial Performance
Financial Performance VieMed Healthcare Inc. • Investor Presentation 14
Slide 15: 2024 results demonstrate strength of the business...
2024 results demonstrate strength of the business... • Net revenues grew 23% Y-o-Y, reaching a new Company record and at high $224M $51M Net Revenue Adjusted EBITDA 1 $12M Free Cash Flow 1 end of expectations • Vent patients increased 14% Y-o-Y • Adjusted EBITDA grew 1 $18M Cash on Hand $0M Net Debt
Slide 16: ...Consistent with our proven track record...
...Consistent with our proven track record... $300,000,000 $250,000,000 $200,000,000 $150,000,000 $100,000,000 $50,000,000 $- 2017 2018 2019 20201 20211 2022 1 2023 2024 2025E3 2 Revenue Adj. EBITDA (1) 2020, 2021 and 2022 Includes $34.3 million, $8.6 million and $2.3 million of COVID-19 sales and s
Slide 17: ...Combined with strong returns to create a compelling valuation
...Combined with strong returns to create a compelling valuation 1 1 Source: S&P Capital IQ Company Share Equity Enterprise EV / EBITDA P/E Debt / Equity Debt / EBITDA ROA ROC ROE (Ticker) Price Value Value 2025E 2026E 2025E 2026E 2024 2024 2024 2024 2024 Public Company: HME Peers AHCO $ 9.53 $ 1,36
Slide 18: 2025 guidance anticipates another strong year...
2025 guidance anticipates another strong year... Core Metrics • Net revenue of $254 million to $265 million 1 • Adjusted EBITDA of $54 million to $58 million 1,2 (21%-23% of net revenue) Directional Commentary on Quarterly Cadence • Year-over-year growth expected to be consistent with prior year • Q
Slide 19: ...And a solid growth plan we can execute
...And a solid growth plan we can execute • Grow active patient base while entering new target markets through geographic expansion • Continue to diversify revenue stream and payor base • Expand technology capabilities to incorporate useful AI tools to drive efficiencies and capture outcome data • E
Slide 20: Appendix
Appendix VieMed Healthcare Inc. • Investor Presentation 20
Slide 21: Sleep therapy growing with GLP-1 adoption
Sleep therapy growing with GLP-1 adoption Increased Engagement GLP-1 adoption boosts patient and provider engagement 16% 2024 VieMed Sleep Revenue Market Opportunity In the general U.S. population, prevalence of all OSA, moderate-to- as a % of Total Revenue severe OSA, and severe OSA was 57.6%, 21.3
Slide 22: Devices and equipment
Devices and equipment At-Home Sleep Testing Tankless Percussion Oxygen Therapy Vests Bi-Level Complex Sleep Respiratory Therapy 73% of Revenue 16% of Revenue CPAP Ventilators VieMed Healthcare Inc. • Investor Presentation 22
Slide 23: Competitive bidding timeline
Competitive bidding timeline Congress enacts Competitive Bidding Round 2021 After initial termination due to errors in the CMS announces unified bidding schedule. process, Round 1 is rebid; 9 CBAs, 9 product CMS then cancels or removes 13 of the 15 categories, including CPAP and Oxygen product categ
Slide 24: Liquidity metrics
Liquidity metrics (expressed in thousands of U.S. Dollars) For the year ended 12/31/24 12/31/23 12/31/22 Cash on hand $ 17,540 $ 12,839 $ 16,914 Working Capital $ 15,554 $ 6,243 $ 20,881 Long Term Debt $ 3,589 $ 6,002 $0 Positioned for growth • The Company maintains a healthy balance sheet with no n
Slide 25: Free cash flow
Free cash flow Free Cash Flow is a non-GAAP financial measure defined as net cash provided by operating activities less cash paid for purchases of property and equipment, net of proceeds from sale of property & equipment. Historically reported amounts of Free Cash Flow for the years ended December 3
Slide 26: Reconciliation of adjusted EBITDA
Reconciliation of adjusted EBITDA1 (Expressed in millions of U.S. Dollars) For the year ended: 2024 2023 2022 2021 2020 2019 2018 2017 Net Income attributable to $ 11.3 $ 10.2 $ 6.2 $ 9.1 $ 31.5 $ 8.5 $ 9.5 $ 7.7 Viemed Healthcare, Inc. Add back: Depreciation and amortization 25.3 21.9 15.6 11.3 9.6
Viemed Healthcare — Investor Presentation (March 2025) on 6ix